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The development of an effective HIV vaccine to prevent and/or cure HIV remains a global 
health priority. Given their central role in the initiation of adaptive immune responses, 
dendritic cell (DC)-based vaccines are being increasingly explored as immunotherapeu-
tic strategies to enhance HIV-specific T cells in infected individuals and, thus, promote 
immune responses that may help facilitate a functional cure. HIV-1-based lentiviral (LV) 
vectors have inherent advantages as DC vaccine vectors due to their ability to transduce 
non-dividing cells and  integrate into the target cell genomic DNA, allowing for expres-
sion of encoded antigens over the lifespan of the cell. Moreover, LV vectors may express 
additional immunostimulatory and immunoregulatory proteins that enhance DC function 
and direct antigen-specific T cells responses. Recent basic and clinical research efforts 
have broadened our understanding of LV vectors as DC-based vaccines. In this review, 
we provide an overview of the pre-clinical and clinical LV vector vaccine studies for treat-
ing HIV to date. We also discuss advances in LV vector designs that have enhanced DC 
transduction efficiency, target cell specificity, and immunogenicity, and address potential 
safety concerns regarding LV vector-based vaccines.
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inTRODUCTiOn
Although antiretroviral therapy has dramatically improved the outcome of HIV infection (1, 2), 
it is not curative. The failure to cure HIV is due to a reservoir of latently infected T cells formed 
in the acute phase of infection that re-establishes virus loads upon treatment interruption, thus 
necessitating lifelong therapy. The development of a vaccine to prevent or cure HIV is, therefore, a 
major public health priority to fight the global epidemic.
There have been extensive efforts to develop an effective HIV vaccine; however, only one of the 
preventive vaccine candidates tested in human efficacy trials afforded even modest protection (3–8). 
Therapeutic vaccine trials for HIV have also failed to show any sustainable impact on viral load and/
or viral reservoirs (9–14). Vaccination strategies that generate sustained, high-quality, HIV-specific, 
adaptive immune responses may be a key component to future success (15–18).
Human trials of HIV vaccines that utilize vector-based antigen delivery approaches have primar-
ily included Adenoviral and Pox vector platforms (3–11, 13). Additional viral and bacterial vectors, 
derived from cytomegalovirus (CMV), listeria monocytogenes, and HIV lentiviral (LV) constructs 
have shown potential in pre-clinical studies, but safety concerns have slowed their development 
(19–22).
In this review, we focus on recent advances in the design of HIV-derived LV vectors for vaccines to 
induce and augment adaptive immune responses. LV vectors have been explored extensively for gene 
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therapy applications, including for treatment of HIV-1 infection 
(23, 24). By contrast, the field is considerably less developed 
regarding their use as HIV vaccines, though pre-clinical and 
early clinical data show promise (20, 21, 25–30). It is important 
to highlight certain distinctions between these two applications 
of LV vectors for HIV, which in large part reflect the genes deliv-
ered and desired target cell. LV vectors integrate and replicate 
in both dividing and non-dividing cells making them efficient 
vehicles to deliver therapeutic genes with long-lived expression. 
LV vector-based gene therapies against HIV aim to confer host 
resistance to infection through delivery of genetic information 
that interferes with HIV entry or replication and, therefore, 
primarily target hematopoietic stem cells (HPSCs) or T cells. 
By contrast, LV vaccines for HIV target antigen-presenting cells 
(APCs) to deliver HIV antigens that are efficiently presented on 
MHC molecules. Dendritic cells (DCs) are the ideal LV vaccine 
targets as they are the most potent APCs and uniquely able to 
initiate primary immune responses and stimulate robust and 
durable antigen-specific T cell responses (31). Moreover, the use 
of LV vectors as DC vaccines offers several advantages over other 
DC antigen-loading strategies, including more sustained antigen 
expression following integration into the target cell genomic 
DNA, endogenous production of antigen for more efficient MHC 
presentation, the ability to encode immunostimulatory genes and 
check point inhibitors to enhance T cell responses, and minimal 
vector immunity when using certain pseudotyped constructs 
[e.g., LV vectors pseudotyped with different vesicular stomatitis 
virus G envelope (VSV-G) serotypes] (20, 29).
Here, we review the pre-clinical and early clinical data regard-
ing the use of LV vectors for DC vaccination strategies against 
HIV-1, and discuss ongoing research to overcome challenges 
relating to LV vector safety and efficacy. In particular, we focus 
on recent advances regarding improved LV vector targeting, 
transduction, and activation of DCs and other APCs to improve 
their immunostimulatory capacity and mitigate safety concerns.
OveRview OF PRe-CLiniCAL AnD 
HUMAn STUDieS OF Lv veCTORS FOR 
Hiv vACCineS
Several pre-clinical studies have demonstrated that LV vectors are 
able to induce strong HIV-specific adaptive immune responses 
(20, 21, 25–29), and preliminary data from an early phase study in 
HIV-infected individuals support these findings (30). LV vectors 
encoding HIV-1 or SIV epitopes induced strong HIV-specific 
cytotoxic T lymphocytes (CTLs), as well as humoral responses in 
both mouse models and human in vitro studies (21, 25, 26, 28, 29). 
Notably, LV vectors have demonstrated superior immunogenicity 
when compared with other vaccine platforms in mice (27, 29, 
32). An HIV-1-based LV vector encoding HIV Gag, Pol, and Rev 
(VRX1023) stimulated more potent and more durable mucosal 
and systemic cellular and humoral responses than administration 
of Ad5 HIV vectors (29). Additionally, no anti-vector immunity 
was detected against the HIV-1-based LV vector, allowing the use 
of a multiple injection approach to augment immune responses 
(29). In other disease models, LV vectors were similarly found 
superior in generating antigen-specific T cell responses in terms 
of both magnitude and longevity when compared to peptide-
pulsed DC vaccines and peptide-adjuvant combinations (27, 32).
In non-human primate models of SIV, macaques that had 
been immunized with two doses of a VSV-G pseudotyped LV 
vector expressing SIVmac239 Gag and then challenged with 
rectal SIVmac251 were protected throughout the acute phase of 
infection (20). A single injection of the LV vector elicited strong 
and diverse Gag-specific T cell responses that peaked at 16 days 
post priming regardless of the dose used, whereas a second dose 
of non-cross-reactive VSV-G pseudotyped LV vectors adminis-
tered 11 weeks later raised more robust and rapid Gag-specific 
T cell responses, albeit similar in breadth. Subsequent challenge 
of high-dose SIVmac251 resulted in infection in all animals; 
however, the acute phase of infection showed a reduction in viral 
replication by more than two orders of magnitude and protection 
against CD4 T cell (CD28+ CD95+) loss. Lower viral set points 
in vaccinated animals were also observed, though these were not 
statistically significant by day 49 post-infection (20).
A first-in-human, phase I/II randomized, controlled study in 
38 HIV-infected individuals receiving antiretroviral therapy is 
currently underway (NCT02054286) (30). In this study, a non-
replicative and self-inactivating LV vector encoding portions of 
HIV Gag, Pol, Nef proteins (TV01, Theravectys) is administered 
via two intramuscular (IM) injections spaced 8 weeks apart. Initial 
analysis revealed that TV01 is safe and highly immunogenic with 
CD4+ and CD8+ T cell responses to multiple vaccine-associated 
epitopes. These CD4+ and CD8+ T cell responses were found 
to be polyfunctional as evidenced by production of multiple 
cytokines and sustained for up to 24 weeks (30). Evaluation of 
ART interruption is reported to be underway, in addition to plans 
for a Phase II study.
Taken together, these pre-clinical and now early clinical find-
ings support the potential therapeutic application of LV vectors 
as HIV vaccines. To improve upon the potency and safety of such 
vectors, it will be critical to use strategies that enhance the target-
ing, transduction efficiency, and stimulation of DCs and other 
APCs.
DC-TARGeTinG APPROACHeS
Initial HIV-1-based LV vectors were generated as VSV-G 
glycoprotein pseudotypes to allow for production of highly 
infectious virus with a broad tropism for target cell transduc-
tion, including non-dividing cells (Figure 1A) (33). The use of 
other glycoproteins for pseudotyping has been explored with 
the intent of minimizing off-target effects, improving safety, 
and enhancing potency. LV vectors pseudotyped with a mutated 
Sindbis virus glycoprotein (SVGmu) confer a natural tropism 
toward human DCs as SVGmu selectively binds to the DC 
surface protein DC-SIGN (CD209) (Figure  1B) (34). Unlike 
standard laboratory-adapted Sindbis virus envelopes that target 
ubiquitously expressed heparan sulfate in addition to DC-SIGN, 
SVGmu contains mutations in the heparan sulfate binding 
site that prevent heparan sulfate-mediated cell entry. A single 
injection of an SVGmu-pseudotyped LV vector encoding tumor 
FiGURe 1 | Design of Lv vectors to preferentially target DCs/APCs. (A) Vesicular stomatitis virus G (VSV-G) glycoprotein-pseudotyped LV vectors possess 
diverse cell tropism, including transduction of non-dividing cells. (B) Sindbis virus glycoprotein (SVGmu)-pseudotyped LV vectors selectively target DCs by binding 
the endocytic receptor, DC-SIGN, while containing mutations in the heparan sulfate binding site to prevent transduction of other cell types. (C) LV vectors 
pseudotyped with measles virus glycoprotein (MVG) mediate direct cell entry via membrane fusion at the plasma membrane. These vectors can be engineered to 
display single-chain antibody (scFV) directed at MHC II to target transduction of APCs. (D) VSV-GS, a binding-defective, fusion competent VSV-G, and nanobody-
pseudotyped LV virions are engineered to bind various DC ligands for targeted fusion.
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antigen or HIV-1 Gag in mice stimulated their DCs to induce a 
durable antitumor or HIV-1-specific immune response, respec-
tively, while inducing only low levels of anti-vector neutralizing 
antibodies (34, 35). Moreover, prime/boost regimens consisting 
of either a heterologous DNA prime/SVGmu-LV-Gag boost or 
successive SVGmu-LV-Gag injections enhanced cellular and 
humoral responses and proved superior to a DNA prime/adeno-
viral vector boost immunization in terms of both the breadth 
and polyfunctionality of the vaccine-induced Gag-specific CD8+ 
and CD4+ T cells. Subsequent modifications of SVGmu, through 
amino acid substitutions in the receptor-binding site and res-
toration of the wild-type furin cleavage, improved proteolytic 
processing and virus maturation and led to enhanced DC-SIGN 
specificity and production yields (36).
Measles virus glycoproteins (MVGs), hemagglutinin (H) 
and fusion (F), have also been used to pseudotype LV vectors 
for DC targeting. A potential advantage over SVGmu and VSV-
G-pseudotyped lentiviruses that require endocytosis for viral 
membrane fusion and cell entry (37) is that MVG-pseudotyped 
lentiviruses fuse at the plasma membrane for direct cell entry. The 
H glycoprotein of the measles virus is responsible for receptor rec-
ognition and confers a natural tropism for both the CD46 recep-
tor expressed on all nucleated cells and the signaling lymphocyte 
activation molecule (SLAM) receptor constitutively expressed 
on memory T cells, thymocytes, select B cells, monocytes, and 
DCs (38). Remarkably, measles virus-pseudotyped vectors were 
shown to be fourfold more infectious in DCs compared to VSV-
G-pseudotyped vectors at an MOI of 10 (39). Moreover, unlike 
VSV-G-pseudotyped lentiviruses that induced DC activation, 
pseudotyping with MVGs did not affect the maturation and 
activation status of the transduced DCs, thereby minimizing any 
unintended stimulation. In effort to develop APC-specific MVG-
pseudotyped LV vectors, mutations were made in the H glyco-
protein’s CD46 and SLAM recognition sites, and the glycoprotein 
was further engineered to display single-chain antibody (scFv) 
directed against major histocompatibility complex class II (MHC 
II) (Figure 1C) (40–42). Resultant LV vectors showed high in vivo 
DC specificity and induced significant CD4+ and CD8+ T cell 
responses, albeit, inferior to the VSV-G-pseudotyped vectors, 
likely owing to the impaired transduction efficiency and stability 
of the chimeric constructs. Mice immunized with a single injec-
tion of the HIV-1-derived LV vector pseudotyped with MHC 
II-targeted MVGs did, however, mount antigen-specific effector 
CD4+ and CD8+ T cells and establish T cell immune memory, 
suggesting their potential for clinical use (41).
An alternative approach to generating DC-specific LV vectors 
is to take advantage of the natural LV budding process and incor-
porate cell-targeting moieties at the viral surface. To this end, 
LV vectors were pseudotyped with a binding-defective, fusion-
competent VSV-G glycoprotein (VSV-GS) and DC-specific 
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single variable regions derived from camel IgG sequences, called 
nanobodies. The resultant virions selectively bind DC receptors to 
allow DC-specific membrane fusion (Figure 1D). This nanobody 
display technology has proven effective at targeting LV vectors to 
murine DCs both in vitro and in situ and has previously been well 
reviewed (43, 44).
A comparison of the different strategies used to develop LV 
vectors for DC-targeted delivery is summarized (Figure 1). These 
approaches carry inherent safety advantages over broadly tropic 
vectors, and it is likely that continued improvements in their 
stability, DC specificity, and transduction efficiency will advance 
their readiness for clinical testing.
STRATeGieS TO enHAnCe  
DC TRAnSDUCTiOn
DC-targeting aside, the development of HIV-1-based LV 
vectors as DC vaccines has been limited by the low efficiency 
with which DCs are transduced. DCs express SAMHD1, a 
phosphohydrolase that depletes the cell of deoxynucleotide 
triphosphates, thereby halting infection of HIV-1-based vectors 
at the level of reverse transcription (45–47). HIV-2 and some 
SIV isolates encode the accessory protein Vpx that counteracts 
this block to infection by binding to SAMHD1 and recruiting an 
E3 ubiquitin ligase complex, CRL4, to mediate its proteasomal 
degradation (48, 49). However, HIV-1 does not encode Vpx and 
lacks a similar mechanism to counteract SAMHD1. Various 
strategies have, therefore, been attempted to deliver Vpx with 
HIV-1-based LV vectors in order to improve their ability to 
transduce DCs.
Initial studies co-administered LV virions with virus-like par-
ticles (VLPs) containing Vpx to facilitate SAMHD1 degradation 
and improve LV vector DC transduction efficiency (50). More 
recently, Sunseri et  al. identified the 10 amino acid packaging 
motif in the P6 protein of SIVmac Gag that is required to package 
Vpx. Introduction of this motif into P6 of the HIV-1 Gag/Pol 
packaging vector allowed for the production of HIV-1 virions 
that contained a high copy number of Vpx molecules in its native 
location (51). The Vpx-packaged HIV-1 vectors infected DCs 
with a two-log increase in titer and allowed for the stable expres-
sion of transgenes or shRNA knock-down of target genes (52). In 
the absence of the Vpx-packaging motif, HIV-1-based LV vectors 
packaged only trace quantities of Vpx and the virus had much 
lower titers on DCs (21, 51, 52). An alternative approach to allow 
Vpx packaging was to fuse Vpx to a cSrc membrane-targeting 
domain (53). Co-transfection of the Vpx-cSrc expression plasmid 
during LV production allowed Vpx to be re-localized from the 
nucleus to the plasma membrane where it could be packaged into 
virion particles during virion assembly. Resultant Vpx-packaged 
lentiviruses encoding antigenic epitopes were shown to efficiently 
transduce DCs and stimulate expansion of antigen-specific CD8 
T cells (54). It has been reported that Vpx-packaging is pos-
sible without any modification to the HIV-1 capsid or fusion 
to cSrc (36), though the Vpx-packaging efficiency is likely to 
be considerably improved by these systems and allow for more 
efficient DC transduction.
STRATeGieS TO enHAnCe Lv  
veCTOR iMMUnOGeniCiTY
In chronic infections, such as HIV, continuous antigen stimulation 
along with other factors leads to immunologic tolerance and CTL 
exhaustion. An advantage of using viral vectors for DC trans-
duction is that the vectors can accommodate large gene inserts 
and express immunostimulatory proteins to serve as adjuvants 
for enhancing or regulating antigen-specific immune responses. 
Effective stimulation of antigen-specific T cells requires three 
signals: MHC-peptide complex recognition by antigen-specific 
T cell receptors (TCR), costimulation by DC surface molecules 
and their T cell ligands (i.e., DC CD80 and T cell CD28), and 
cytokine priming mediated by DC secretion of soluble cytokines. 
We previously showed that Vpx-packaged LV vectors expressing 
the DC stimulatory protein CD40 ligand (CD40L) fused to a 
single influenza or HIV viral epitope efficiently transduced DCs, 
causing the cells to mature and secrete proinflammatory and Th1 
skewing cytokines (e.g., TNF-α, IL-12, and IL-6) that enhanced 
antigen presentation, and thus stimulated robust expansion of 
influenza or HIV-specific CTLs (21). Furthermore, the proin-
flammatory cytokines transiently released by DCs transduced 
with Vpx-vectors expressing CD40L reactivated latent HIV-1 
provirus in latency models, supporting the use of such vectors in 
a two-pronged, “shock and kill” approach for reducing the latent 
reservoir and facilitating a functional cure (21). Goyvaerts et al. 
similarly capitalized on the ability of IL-12 to enhance expansion 
CD4+ Th1 cells and cytotoxic effector cells and showed that DCs 
transduced with LV vectors expressing IL-12-enhanced antigen-
specific CTLs in vivo (55). Others developed LV vectors express-
ing antigenic epitopes in tandem with granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) or 
GM-CSF and IFN-α to enhance the longevity of transduced DCs 
and promote a more durable immune response (56–59).
In addition to enhancing immune responses, reversing 
immunologic tolerance by interfering with the programed death 
1 (PD-1) pathway has been a well-studied means of restoring 
the function of exhausted antigen-specific CD8 T cells (60, 61). 
PD-1 is upregulated during chronic infection with HIV and its 
increased binding to its ligand, PD-1 ligand (PD-L1), mediates 
virus-specific CD8 T cell exhaustion by impairing the ability of 
T cells to become activated, proliferate, and produce cytokines. 
Blocking the PD-1/PD-1L inhibitory signal with an anti-PD-
L1 antibody led to an enhanced HIV-1–specific CD8+ T cell 
response in mice immunized with DCs transduced with a LV 
vector expressing HIV-1 Gag (62). Interfering with PD-L1/
PD-1 costimulation via LV vectors expressing soluble PD-1 or 
shRNA against PD-L1 also led to enhanced antigen-specific CTL 
responses (63–66), further highlighting the potential feasibility 
and importance of disrupting the PD-1/PD-L1 interaction in 
future LV vaccine strategies.
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ADDReSSinG SAFeTY COnCeRnS wiTH 
Lv vACCine veCTORS
Although DC targeting can minimize the off-target transduction 
of LV vectors, the use of HIV-derived LV vectors raises inherent 
safety concerns. These risks primarily relate to the formation of 
infectious virus and potential for host mutagenesis, and have 
been addressed in multiple ways to maximize safety. Several 
aspects regarding the design of LV vectors render the formation 
of replication-competent virus and subsequent infection exceed-
ingly low (20). The risk of reconstituting pathogenic parental 
HIV-1 virus is eliminated by providing the only HIV-1 structural 
and enzymatic proteins required for the formation of LV virions 
in trans and using heterologous envelopes (e.g., VSV-G) such that 
LV vectors support only a single round infection. Furthermore, 
LV vector constructs generally lack accessory and regulatory 
genes, such as vif, vpr, vpu, and nef, that are required for efficient 
replication in vivo (67). Finally, self-inactivating vectors can also 
be designed that lack the 3′-LTR region of the viral promotor 
and enhancer.
The other major safety concern with LV vectors is the risk for 
potential mutagenesis caused by insertion of the viral genome 
into the host genome. The risk of insertional mutagenesis remains 
controversial but is likely very low as it has not been described 
with HIV-derived LV vectors in gene therapy trials to date (20, 
23, 24). However, these concerns were highlighted in studies 
that used a retroviral vector derived from the Murine Moloney 
Leukemia Virus (MoMLV) in two SCID-X1 gene therapy trials 
(68, 69). In these studies, several cases of leukemia occurred 
post-treatment, thought to be caused by the transactivation of a 
proto-oncogene by a viral enhancer rather than a direct effect of 
integration (69). Options to offset this possibility include using a 
promotor that lacks enhancer activity, or the use of integration-
deficient LV vectors (IDLVs) that cannot insert themselves into 
the host genome. It should also be highlighted that in the case of 
LV vectors for vaccination purposes as opposed the gene therapy, 
the likelihood of a detrimental effect caused by insertional 
mutagenesis is reduced as the transduced APCs do not proliferate 
and will likely be cleared by the subsequent CTLs that are formed.
The use of IDLVs generated by the expression of a catalyti-
cally inactive integrase is the most fail-safe means to mitigate any 
potential risk for insertional mutagenesis (70). Instead of insert-
ing into the host genome, episomal DNA accumulates in the 
nucleus, resulting in transcription and efficient expression of the 
target gene (71). IDLV have been shown to be immunogenic with 
the ability to elicit both humoral and cell-mediated responses 
after IM and mucosal administration, although somewhat 
weaker than integrating LV vectors (72, 73). It remains poorly 
understood why IDLV have been less potent as vaccine vectors in 
pre-clinical studies compared with integrative LV vectors. Unlike 
integrated DNA, episomal DNA may be diluted in dividing cells 
over time. However, given that APCs/DCs are non-proliferating, 
decreased expression of target genes over time would seem 
less likely to impact their efficacy as vaccine vectors. Despite 
the weaker potency that has been observed when compared 
with integrative LV vectors, IDLV have been effective in stable 
transduction following IM administration in mice (74, 75) and 
has proven effective in multiple models of infection, including 
West Nile virus (76), HPV-associated tumors (77), and malaria 
(78). In terms of pathogens acquired via a mucosal route, includ-
ing HIV, both mucosal immune responses and systemic immune 
responses are desirable for protection. Mucosal immunization 
using IDLV by various routes has shown promise in achieving 
protection at these surfaces in mouse models (79, 80). CD8+ T 
cell responses were observed in the gut in the lamina propria 
following IM vaccination with IDLV, but an adjuvanted sub-
lingual protein boost was required in order to induce mucosal 
IgA responses (80). Intranasal (IN) vaccination with an IDLV 
expressing influenza nucleoprotein (NP) was compared to IM 
vaccination and both were found to induce NP-specific B and 
T cell responses, however, only the IN route protected from 
influenza virus infection (79).
A human vaccine trial combining these many safety 
measures in a phase I dose-escalation study in solid cancers 
is currently under way (NCT02122861) (81). This trial uses 
replication-incompetent, IDLV vectors expressing full-length 
NY-ESO-1, engineered to target DC-SIGN (LV305, Immune 
Design) and induce tumor-specific CTLs in patients with 
advanced NY-ESO-1 expressing melanoma, sarcoma, breast, 
lung, or ovarian cancers. Early results from dose escalation in 
12 patients with sarcoma demonstrated safety up through the 
highest dose (1010  vg) administered intradermally (ID), with 
only grade I/II adverse events. The early immunogenicity from 
only the lowest dose group (108 vg, N = 6) has been reported 
following receipt of 3–4 ID injections q3weeks, and found to 
generate strong T cell responses and some early evidence of 
antitumor effect (81).
COnCLUSiOn
HIV-1-derived LV vectors are an effective tool for targeting DCs 
and inducing potent HIV-specific adaptive immune responses. 
The best means to preferentially target DCs to maximize both 
safety and immunogenicity of LV vectors is a matter of ongoing 
investigation and remains a key issue. A better understanding of 
HIV restriction factors, such as SAMHD1, and their counterac-
tion by viral proteins, such as Vpx, has lead to the development 
of vectors with high DC transduction efficiencies and reinvigor-
ated the DC vaccine field. Incorporation of immunostimulatory 
genes into LV vectors as adjuvants has further improved their 
immunogenicity. Additionally, the safety of LV vectors has been 
enhanced through developments in IDLVs and substantiated by 
their exploration in clinical trials. Taking together, therapeutic 
LV vector-based DC vaccines have the potential to alter the tradi-
tional vaccine landscape and may provide a means to contribute 
to functional cure strategies for HIV, as well as other diseases 
where antigenic targets have been identified.
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